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Abstract
This paper describes work in collaboration with a large dermatology directorate in
South Wales to map out current patient flow and activity levels for psoriasis
management. Psoriasis is a chronic skin disease that often has a high impact on
patient quality of life. Clinical services for patients with moderate to severe
psoriasis tend to be located in secondary care hospitals. The range of services that
were studied, their geographical location in relation to the distribution of
population, and the population demographics in this health board were not
unique; similar profiles for these factors can be found throughout the NHS in
England and Wales. The model was created to analyse patient flow through
different therapies, with the aim of maximising throughput of patients, eliminat-
ing bottlenecks, improving patient access to services and improving patient safety.
It was shown that reducing waiting times and improving access to phototherapy
would lower overall service costs, as fewer patients would subsequently require
systemic and biologic therapies. The model has been used to quantify how recent
year-on-year increases in overall spend on psoriasis treatments might be slowed
and eventually halted. This would require reallocation of notional cost-savings
generated by reducing the rate of increase in the drug spend to fund the
development of a more balanced and accessible network of more basic psoriasis
services.
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Introduction
The demand for healthcare services in the U.K. continues to increase while
economic pressures mean that the National Health Service (NHS) will likely
face an effective budget reduction of £36 billion by 2018 (HM Treasury,
2013). The deﬁcit between supply and demand proves to be economically
costly and typically has a detrimental impact on factors such as waiting
times. Operationally, healthcare systems are a complex combination of
resources (staff, equipment, operating rooms, hospital beds, etc.) and patient
demand (which can possess signiﬁcant levels of variability). Extensive
research has demonstrated that use of discrete-event simulation (DES) is an
appropriate and effective tool for modelling complex healthcare systems
and assisting with operational decisions ( Jun et al, 1999, Harper, 2002; Fone
et al, 2003; Brailsford et al, 2009; Katsaliaki & Mustafee, 2011).
In this paper, we consider the provision of secondary care services for
treatment of psoriasis, a common chronic skin disease, in a large health
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board in South Wales. Psoriasis has a population preva-
lence of 1.3–2.2% (Parisi et al, 2011) and sometimes affects
the joints. It is not yet possible to predict which treatment
will be safe, effective and convenient for individual
patients with psoriasis. Treatment tends to be hierarchical,
commencing with topical therapies prescribed by general
practitioners (GPs) in primary care (creams and oint-
ments), before referral to secondary care for more potent
options prescribed by teams led by consultant dermatolo-
gists (NICE Clinical Guideline 153, 2012). Secondary care
treatment of psoriasis usually commences with ultraviolet
therapy (NICE Clinical Guideline 153, 2012) which is
given two to three times per week for up to 10 weeks.
Patient access to phototherapy depends on geographical
location of the phototherapy unit relative to the patient’s
home or workplace, and the capacity of the phototherapy
service (Anstey, 2013). In patients who fail with photo-
therapy or who are unable to access the service, systemic
drugs (tablets and occasionally injections) are the next
option. Most of these drugs work by suppressing adaptive
immunity, requiring regular blood tests to monitor for
drug-induced toxicity and dosage optimisation. In patients
with psoriasis who fail to respond to standard systemic
therapies, biologics may be indicated (NICE Clinical
Guideline 153, 2012). The ﬁrst biologics for psoriasis were
approved by NICE in 2006 for moderate to severe psoriasis
in patients who had failed to respond, were intolerant of,
or had contraindications to standard systemic therapies
and PUVA (a form of phototherapy). In a subsequent NICE
Clinical Guidance (NICE Clinical Guideline 153, 2012),
omitting phototherapy was recommended for patients
who responded poorly or where phototherapy was poorly
tolerated; furthermore, it was advised that patients should
not have phototherapy if accessing treatment was difﬁcult
for logistical reasons such as travel, distance, time off work
or immobility (NICE Clinical Guideline 153, 2012). Biolo-
gic therapies cost close to £10,000 per patient per annum
(Eedy, 2008) and are typically prescribed for long-term use
in an open-ended fashion.
In summary, the model of psoriasis care described above
consists of multiple therapy lines, which may be thought of
as a set of possible care pathways depending on patient
need. Each therapy line has a number of potential treat-
ments. Furthermore, each treatment in each therapy line is
administered and monitored in different ways with varied
levels of required resources. Thus overall management of
psoriasis care for large hospital dermatology departments,
providing care for large volumes of patients across multiple
therapy lines within resource constraints, is a complex
process. An overview of psoriasis treatments is provided in
a NICE pathway (NICE Clinical Guideline 153, 2012).
Working with the Dermatology Directorate within the
Aneurin Bevan University Health Board (ABUHB), South
Wales, the project explored the potential use of DES to
provide a model for the allocation of treatment therapies
that capture sufﬁciently the complexities of the patient
ﬂows in the current system. The motivation was to use this
model to provide recommendations on alternative service
conﬁgurations to help improve efﬁciency, improve access
to high-volume low-cost therapies, reduce waiting times
and lower overall service costs. In particular, the focus was
to assess the impact of increased capacity and improved
geographical access to phototherapy on other more costly
and potentially toxic psoriasis treatment options. The
authors are not aware of any other literature on opera-
tional research and simulation modelling applied to the
delivery of healthcare services for psoriasis patients, thus
this is seemingly a novel application.
Background
ABUHB serves a large geographical area of South Wales,
providing services to a population of approximately
600,000. Parts of the region are among the most deprived
areas of the U.K., and include patients from areas of inner-
city deprivation, post-industrial urban decline as well as
deeply rural, relatively isolated communities. Such diver-
sity adds to the complexity of planning and organisation
of services across ABUHB.
The target relating to referral to treatment time in Wales
is a maximum of 36 weeks (Welsh Government Report,
2011). Furthermore, the aim is to ensure that aminimumof
95% of patients access planned services within 26 weeks.
In July 2012, it was reported this target was being met
in ABUHB with 92.7% of all patients seen within 26 weeks
and 100% compliance within 36 weeks (National Assembly
for Wales Research Note, 2012). However, the Dermatology
Directorate in ABUHB was not performing as successfully as
the overall health board. Psoriasis care in secondary care
is costly as psoriasis is common and patient care is labour-
intensive (systemic therapy monitoring; dermatology day
case treatments; phototherapy staff; inpatient care) and
includes the prescription of very expensive drugs (ciclosporin,
Fumaderm, biologics). Therefore, this project was initiated to
evaluate ways in which access to psoriasis treatments could
be improved.
Psoriasis is a chronic relapsing dermatological disease
that causes ﬂaky, crusty and red patches of skin, often
identiﬁed by silvery scales. Severity of psoriasis varies
greatly (Krutman et al, 2008). For some it is merely an
irritation, while for others it can have a major impact on
their health-related quality of life (Krueger et al, 2000).
Although there is currently no cure for psoriasis, there are a
variety of specialist therapies that are effective in control-
ling psoriasis. In NHS Wales, these therapies are obtained
through GP referral to a local health board, usually dedi-
cated to dermatology and rheumatology services.
Treatments for psoriasis fall into four main categories
that respectively deﬁne the varied lines on therapy avail-
able: topical therapy, phototherapy, systemic oral therapy
and biologic therapy (NICE Clinical Guideline 153, 2012).
These four categories differ in their route of administration,
necessary reviews, monitoring and, consequently, resources
required. Furthermore, the order described above is usually
the natural course a patient is expected to follow, whereby a
patient will only progress to the next therapy line upon
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failure, toxicity or intolerance of the current treatment.
Importantly, costs involved tend to increase as patients
progress through the therapy lines. Therefore, it is impor-
tant to ensure patients are allocated their optimum, and
most cost-effective treatment. NICE guidance for psoriasis is
underpinned by comprehensive health economic analysis
(NICE Clinical Guideline 153, 2012); if clinicians adhere to
the guidance, biologics will usually be resourced by the
NHS. This is important as it prevents the withholding of
effective high-cost treatments from patients who qualify
according to NICE criteria.
There are a number of dermatology clinics within ABUHB,
each of which is run by a variety of medical personnel
including: consultant dermatologists, GP clinical assistants,
clinical nurse specialists, dermatology specialist registrars (a
training grade for prospective consultant dermatologists)
and general nurses. At these clinics, patients with psoriasis
are appropriately managed and given access to the available
therapies listed above according to expert advice.
Development of a patient flow simulation model
The provision of available therapies for psoriasis in ABUHB
may be considered as a complex network of queues and
activities, thus lending itself to being modelled by DES. For
the purposes of handover and reusability, a Simul8 model
coupled with a bespoke user-friendly Excel interface was
developed. A brief overview of the data and model struc-
ture is now described.
Mapping patient pathways
An integral part of the process of generating a fully
validated patient ﬂow simulation model is through careful
design and construction. This ensures that the ﬂows
accurately represent real-life patient pathways. All avail-
able psoriasis therapies were included along with all the
necessary medical review processes. A conceptual model
describing patient pathways was constructed with the
assistance of a number of key medical professionals in the
dermatology directorate.
The sole patient entry point to the system is through GP
referrals to the dermatology directorate. New patients are
initially seen by one of the six consultant ABUHB derma-
tologists, for whom there is currently a waiting list of
approximately 28 weeks. Following a diagnosis of psoria-
sis, each consultant assigns a patient to one of the various
lines of therapy. These are: topical treatments (ﬁrst line),
phototherapy (second line), systemic therapy (third line),
biologic therapy (fourth line), or in rare cases admitting a
patient immediately to the ward for inpatient care.
Furthermore, if a clinician performing a review believes
there is sufﬁcient improvement in a patient’s condition, it
is possible to assign them a period of no treatment.
Patients can move around the therapy lines in the system
according to success or failure of treatment.
A screenshot of the developed Simul8 model, showing
the complexities of pathways, is shown in Figure 1. Given
the variety of pathways and processes, Figure 1 is shown to
provide the reader an appreciation of the system rather
than all the speciﬁc details. Each therapy line however has
been mapped onto Figure 1 to show the major stages of
patient care, and each line is brieﬂy introduced below.
● Topical therapy: Some patients are deemed not to have
severe enough psoriasis to receive second line or higher
therapies (NICE Clinical Guideline 153, 2012). There-
fore, consultants occasionally ask the patient to use
topical therapies to treat psoriasis. Often, complex com-
binations of these topical treatments are given to the
patient. However, as all these treatments can be pre-
scribed by GPs, it is often assumed that the patient has
tried some topical therapy before being referred to the
dermatology clinic. Therefore, few patients are asked to
use topical treatment alone.
● Phototherapy: Phototherapy is one of the more popular
options prescribed by consultant dermatologists for new
psoriasis patients (NICE Clinical Guideline 153, 2012).
There are two phototherapy clinics within ABUHB: one
at St. Woolos Hospital (SWH) in Newport and one at the
newly built Ysbyty Ystrad Fawr (YYF) in Ystrad Mynach.
There is currently a waiting list of approximately 16
weeks for SWH and 4 weeks for YYF. Phototherapy
usually involves patients attending for a few minutes
three times per week for up to 10 weeks. Following a
course of phototherapy, a patient will either leave the
system if they have responded well, or will request a
review with a clinician. At this review, other options
considered included further phototherapy or other
treatment therapies.
● Systemic therapy: Modelling systemic therapy was a very
complex process that required good understanding of
the system and reliable estimates from the medical staff.
The modelling utilised the protocol for reviews for
patients with psoriasis, where the inter-review times are
differently deﬁned for each of the four compounds
(treatments) available: methotrexate, acitretin, Fuma-
derm and ciclosporin. NICE clinical guidance for sys-
temic therapies excludes Fumaderm as this novel drug is
not yet licensed for use in the U.K. However, Fumaderm
was included in the current study as it is extensively used
by the consultant dermatologists at ABUHB. These sys-
temic drugs can be stopped at any stage during the course
of treatment, either at the discretion of the clinician, or at
the patient’s request. Reasons for stopping include a lack
of observed clinical effect, unacceptable side effects or
drug-induced organ toxicity. In this situation, patients
are prescribed a different systemic compound, or may be
referred for an alternative therapy line.
● Biologic therapy: The sub-system of biologic therapy is
similar to that of the continual review system of systemic
therapy. However, it was more straightforward to model
as the reviews are performed at regular intervals of
3months for all compounds (treatments). Each of the four
compounds used (etanercept, adalimumab, inﬂiximab
and ustekinumab) have different efﬁcacy rates. Addition-
ally, variation in dosage, frequency of administration and
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route of administration provides options for shared deci-
sion making between the prescribing dermatologist and
their patient.
● Inpatient care: Patients with severe, poorly controlled
psoriasis may occasionally require inpatient care at
SWH. Occasionally, such patients may become gener-
ally unwell, requiring more intensive nursing care on a
high dependency care unit.
Data sources
Due to the complex structure of the therapy lines, there
were a large number of data considerations. The data
used in this project had to be extracted and manipulated
from a number of sources. In ABUHB, an online tool is
utilised to store patient information and hospital
appointments. A time-dependent cluster sample was
extracted using this tool, which encompassed all patients
who had a psoriasis-related appointment scheduled in
January 2012. Any patients in this cohort then had their
entire treatment history recorded. In total, 521 appoint-
ments were recorded for 224 patients.
Phototherapy data had to be manually sourced from the
ﬁling cabinets in the phototherapy unit. In total, 215
courses of treatment were recorded for 130 patients. Data
for biologic therapy was provided by ABUHB and included
the sequence that the therapies were given to each patient.
Data for of 69 admissions to the dermatology inpatient
unit (covering the period August 2010 – July 2012) was
also obtained.
It was evident through initial consultations with various
members of the clinic staff that a number of data require-
ments would not be readily available. Therefore, seven
semi-structured interviews were conducted with medical
personnel. This allowed the staff to impart their knowledge
and expert opinion, by providing some numerical estimates
for various parts of the model. Furthermore, by performing
these interviews independently, the model was enabled
to capture the variability (relating to behavioural aspects)
between the decisions that the consultants take in clinic.
The necessary parameters for the model were appropri-
ately derived, using various data manipulation packages
including SAS, Excel and @Risk. Parameters that were
derived included those for
● inter-arrival times;
● service rates and distributions for appointments, length of
treatment(s), wash-out periods and inter-review times;
● probabilities representing various decisions in the system;
● success rates for all treatments;
● estimated capacities for the two phototherapy clinics
and the availability of beds for inpatient care; and
● varying costs associated with the model, including
treatment costs, resourcing costs and phototherapy
equipment costs.
Runtime parameters
The simulation clock ran daily from 08:00 to 18:00 (dura-
tion of 10 h). A warm-up period of 1 year was selected in
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Figure 1 Psoriasis therapy lines captured in the simulation model.
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order to stabilise the other parts of the system. This time
frame was chosen as upon investigation, it appeared that
the system was running at a stable point by this time,
where the numbers and waiting lists reﬂected real practice.
The length of time for which actual results were collected
and analysed was chosen to be 3 years past this initial
warm-up period. One hundred iterations were run in the
trials, unless otherwise stated.
Veriﬁcation and validation
For model veriﬁcation, any parts of the system that called
parameters from the Excel interface had to be appropriately
checked. All parameters were carefully inspected and subject
to via extreme values testing; by setting the parameters to
extremely large and extremely small values. The system was
then run for each parameter to observe whether the changes
made were reﬂected in the behaviours of that particular
model entity. All components were fully veriﬁed through
thismethod. Formodel validationwe adopted bothwhite box
and black boxmethods (Kleijnen, 1995). Frequent visits were
made to the Academic Dermatology Unit at SWH. A number
of preliminary discussions with medical personnel allowed
for development of the model. Pathways and entities were
altered accordingly, if required. Furthermore, observation of
patients attending a number of clinics enabled a more
thorough consideration of timings through the system.
Operational validation compares the results from the
simulation model with a suitable reference to show that the
model can support its intention. For this project, this was
performed by comparing the waiting lists and number of
patients on each treatment therapywith the responses from
the interviews or the data collected. For example, an
important waiting list is for phototherapy treatment. It was
imperative to model this well, as the focus of the later part
of the project was observing the effect of a number of
operational changes to the system on waiting lists for
phototherapy. The medical physicist suggested that the
typical length of time of the waiting list for SWH was 16
weeks, while it was 4–5 weeks for YYF. The simulation
model generates an average queueing time of 113.67 days
for SWH (95% conﬁdence interval is (105.54, 121.8)) and
30.93 days for YYF (95% conﬁdence interval is (25.24,
36.62)). Therefore, the lengths of time on the waiting lists
generated by the simulation model are of a similar order
and in fact are not statistically signiﬁcantly different at the
5% level. Similar statistical analyses were conducted for
other key parameters and overall it was concluded that the
simulation model was successfully tested to be working as
intended, and furthermore replicates clinical practice well.
A full account of all data parameters and model function-
ality may be seen in Putman (2012). For the purposes of this
paper and conciseness, we have presented only the most
important elements.
Investigation of changes to clinical practice
Through discussion with the ABUHB staff, it was evident
that many patients were excluded from phototherapy due
to the length of the waiting lists and geographic disper-
sion. This meant that many patients were missing out on
phototherapy by being routed to systemic therapies. By
allowing a larger proportion of patients to reach third-line
therapies, the systemwas inundated with patients requiring
frequent reviews. Furthermore, arrival within third-line
therapies also opened up the subsequent possibility of
biologic therapies. The simulationmodel also demonstrated
phototherapy (second-line therapy) as a major bottleneck
in the system. Therefore, the scenarios below were identi-
ﬁed with the intention of reducing the length of time that
patients spend on phototherapy waiting lists. Improving
access to phototherapywas another issue that was explored.
Study 1: Sensitivity analysis of current capacity
Observation of the phototherapy unit at SWH showed that
it was operating below capacity. It is hypothesised that this
was due to the ﬂexible nature of patient scheduling for
subsequent treatments. Patients were not allocated a speciﬁc
appointment time but instead a time that is suitable for both
parties was negotiated (e.g. ‘around midday’ was often
heard). Another feasible way to increase current capacity is
through empowering the patients to undergo their photo-
therapy at the two existing units outside of opening hours.
This involves teaching the patient how to use the photo-
therapy equipment and how to control their doses. This
may be advantageous for some patients as having the option
to attend the phototherapy unit between, say, 05:00 and
08:00 would allow them to undergo their treatment before
work. However, this approach is novel, with a single
preliminary study published (Yule, 2013) and no deﬁnitive
clinical governance framework for safe and effective provi-
sion of this model of care. Therefore, it was considered
interesting to investigate the effect on waiting lists if the
capacities of phototherapy units were increased accordingly,
with consideration of the same demand.
For each phototherapy unit, capacity estimates were
incrementally altered from the current capacity. The simu-
lation model was used to evaluate the impact of the
waiting time at each capacity change. Figure 2 summarises
the average time patients spend on the waiting list. The
95% conﬁdence intervals are also presented.
For each discrete increment change in capacity (i.e. the
unit can handle an additional patient), a 2.9% change
from baseline in SWH capacity, and a 4% change from
baseline in YYF capacity, is reﬂected. It is evident that
waiting lists are reduced signiﬁcantly, even in the case that
both units’ capacities were only increased by 10%. Further
reduction is seen by a 20% increase, although not as
signiﬁcant. Additionally, it is apparent that the effect of
increasing the capacity plateaus for SWH after an increase
by four to six patients, and for YYF, after an increase by
two to four patients.
Study 2: Equal allocation to SWH and YYF
As previously noted, currently more patients are routed
towards the phototherapy unit at SWH than YYF. A particular
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scenario posed by the staff concerned the effect of attribut-
ing equal quantities of patients to each unit in an attempt
to reduce the waiting list for SWH. This was modelled by
matching available resources (human resources, equipment
and opening hours) at both units. The probability of a
patient choosing YYF and SWH was also equal. As waiting
lists were expected to diminish, it was postulated that more
patients would be open to the choice of phototherapy.
Therefore, the decision for all consultants to choose photo-
therapy was accordingly increased to reﬂect the higher
likelihood of patients choosing phototherapy.
Table 1 shows the mean difference from baseline with
the corresponding conﬁdence interval. The percentage
difference ratio from baseline is also shown in brackets.
Paired t-tests were performed to show that all indicators
were statistically signiﬁcantly different from the baseline
model at the 5% level.
Study 3: Additional phototherapy units
A further method to reduce phototherapy waiting lists in
ABUHBwas to create additional phototherapy units at new
geographical locations. In this scenario, the treatment
would occur in some other chosen hospitals within the
ABUHB catchment area. The suggested three additional
units were located at Abergavenney, Monmouth and
Chepstow. Therefore, patients would be strategically tar-
geted from more remote areas in ABUHB to undergo their
phototherapy at these units, thus improving access to
phototherapy services.
It was necessary to deduce what proportion of patients
would be attributed to each phototherapy unit. Using
geomapping analysis, each postcode polygon and its
population were assigned to a hospital. Figure 3 shows
how the postcode districts were assigned to each photo-
therapy location. It is evident that the chosen destinations
geographically cover the ABUHB area well. The popula-
tions of each hospital unit were calculated and proportions
were derived. Due to increased provision of services, it was
logical to assume that waiting lists would reduce under
this scenario, and hence that more patients would be open
to the option of phototherapy. Therefore, the proportion
of routing into the different lines of therapy was changed
for each consultant.
Table 2 shows the mean difference from baseline with
the corresponding conﬁdence interval. The percentage
difference ratio from baseline is also shown in brackets.
Paired t-tests were performed to show that all indicators
were statistically signiﬁcantly different from the baseline
model at the 5% level, thus localised provision of photo-
therapy would be highly beneﬁcial.
Discussion and recommendations
The focus of the project was on mapping the ﬂow of
psoriasis patients through available therapies in ABUHB
using DES. Following development and validation of a
simulation model, a number of alternative scenarios were
investigated. The results of this analysis conﬁrmed that the
existing provision of services for psoriasis management
was not performing as efﬁciently or as cost-effectively as
possible.
By performing a sensitivity analysis on the current capa-
cities of SWH and YYF, possible reduction in length of time
on waiting lists was seen. It was observed that by increasing
capacities (number of available slots for patients) by just
10%, the length of time on waiting lists could decrease by
79.5 and 79.8%, for SWH and YYF, respectively. This is a
feasible operational change as the phototherapy units could
potentially be opened out of hours, enabling the patient to
undergo their phototherapy course without the medical
staff. This resonates with the recent advice by the British
Association of Dermatologists, www.bad.org.uk. Alterna-
tively, there appears to be scope for improved patient
scheduling to increase the number of patients who can be
seen in the clinics, thus ABUHB are recommended to
examine this further.
Another feasibility scenario was matching the capacities
of SWH and YYF phototherapy units. Currently, the same
equipment exists at YYF as SWH. However, due to shorter
opening hours and less staff, fewer patients are managed at
YYF. By opening to the same hours as SWH and providing
matched stafﬁng levels, it was expected that YYF could
absorb a great deal of demand from the phototherapy
Figure 2 Plot of changes in average length of waiting lists
resulting from capacity changes at SWH and YYF phototherapy
units.
Table 1 Summary of results for matching capacities at
SWH and YYF phototherapy units
Mean 95% CI
SWH waiting time −107.2 days (−107.7, −106.8)
(−93.2%)
YYF waiting time −20.1 days (−20.3, −19.8)
(−67.2%)
Cost −£118,350 (−130,819, −105,881)
(−4.0%)
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waiting lists. When the model was altered to reﬂect this
change, waiting lists at SWH were reduced by 93.2% and
waiting lists at YYF were reduced by 67.2%. Additionally,
the simulation model suggests that costs throughout the
system would be reduced by 4%, a difference of £118,350
over 3 years. These cost savings are attributed to a 7%
reduction in the number of patients who engage in
systemic therapy and a 5% reduction in the number of
patients on biologic therapy. Although the model does not
account for staff costs in phototherapy, ABUHB have
indicated that these would be signiﬁcantly lower than the
potential cost savings.
Finally, the scenario of opening additional photother-
apy treatment units was considered. Results from the
model showed that wider geographical coverage by open-
ing new phototherapy units would improve access and
reduce overall costs within the system. Length of time on
waiting lists was reduced by 72.7% at SWH and 36.1% at
YYF. Furthermore, there were signiﬁcant costs savings of
8.1%. In real terms, this is the equivalent to £237,765 over
3 years. Such cost savings are a result of a predicted 4%
reduction in the number of patients who engage in
systemic therapy and a 15% reduction in the number of
patients on biologic therapy. However, it is recognised that
such cost savings would be notional rather than real. The
modelling project was based on the assumption that by
studying the whole system, resources released from one
area could be reallocated to another area. The model
suggests that such targeted reinvestment within the sys-
tem would alter the dynamics of the whole system away
from the currently unsustainable year-on-year increases in
biologic prescribing.
The dermatology directorate of ABUHB were advised
to give serious consideration to the potential beneﬁts of
any of the identiﬁed strategies, as the model predicts that
they would prove to be beneﬁcial not just by signiﬁcantly
reducing waiting times but providing large cost savings to
make the service more sustainable in the future.
DES is a data-intensive process, therefore there were a
large number of data requirements. Data were manually
extracted from various sources. In the absence of complete
data, other methods were employed in an attempt to gain
some insight into how the system of psoriasis patient ﬂow
Figure 3 Map of postcode districts assigned to each phototherapy unit.
Table 2 Summary of results of localised phototherapy
Mean 95% CI
SWH waiting time −83.6 days (−83.9, −83.3)
(−72.7%)
YYF waiting time −10.8 days (−11.1, −10.5)
(−36.1%)
Cost −£237,765 (−253,419, −222,111)
(−8.1%)
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performs. For example, semi-structured interviews with
the staff were conducted and sampling from hand-written
patient notes was necessary. Naturally, more complete
quantitative data would have been advantageous and thus
naturally we acknowledge such limitations, but have used
veriﬁcation and validation methods to be satisﬁed that the
model is adequately reﬂecting real-life processes. ABUHB
have been advised to implement a database system
throughout dermatology services.
Conclusions
Through careful and collaborative design, a DESmodel was
developed and successfully validated to show that it
replicates current patient ﬂows of psoriasis patients in the
Aneurin Bevan University Health Board (ABUHB) in South
Wales. The model successfully represents the stochastic
nature of various patient or clinical choices.
A number of alternative service conﬁgurations were
explored by appropriately altering the simulation model
or by manipulating the decision variables to evaluate the
effect on several key performance indicators, including
length of time on waiting lists, and costs. These alternative
designs were selected through discussion with the staff in
the dermatology directorate and were all aimed at improv-
ing waiting lists and access to phototherapy. By achieving
this, it is hoped that fewer patients would require referral
to third- or fourth-line therapy; hence signiﬁcant opportu-
nities for cost reallocation within the system. The identi-
ﬁed scenarios demonstrated signiﬁcantly reduced waiting
lists and revealed potential cost reallocation opportunities.
This is particularly important for the health board at a time
with rising demand and ﬁnancial pressures. Reconﬁguring
the services as suggested would help to provide a sustain-
able service while improving patient safety by reducing the
rate of referral to more complex and risky treatments. This
project has gone a long way to try and understand the
complex behaviours and interactions between patients
and staff in the system of psoriasis management in
ABUHB. It is hoped that the veriﬁable results shown in
this project will lead to implementation of a suggested
strategy in ABUHB, or at least provide a framework for
development of this work in the future. In order to achieve
this aspiration, a signiﬁcant expansion of phototherapy
services is needed, which this model predicts will lead to
long-term savings through reduced spending on high-cost
and higher-risk treatments.
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